Nexalin Technology (NXL) Long-Term Deferred Tax (2021 - 2022)
Nexalin Technology's quarterly Long-Term Deferred Tax came in at $3.3 million in Q4 2022, up 12.91% year-on-year from $3.0 million in Q4 2021, and up 12.91% quarter-over-quarter from $3.0 million in Q4 2021.
Nexalin Technology has reported Long-Term Deferred Tax for 2 years, with the latest figure at $3.3 million in Q4 2022.
- For the quarter ending Q4 2022, Long-Term Deferred Tax rose 12.91% year-over-year to $3.3 million; the trailing twelve-month figure through Dec 2022 stood at $3.3 million (up 12.91% YoY), and the FY2022 full-year result was $3.3 million, up 12.91% from the prior year.
- Long-Term Deferred Tax for Q4 2022 stood at $3.3 million, up from $3.0 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $3.3 million in Q4 2022, with the low at $3.0 million in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3.34 Mn |
| Dec 31, 2021 | 2.96 Mn |